ZNTL
Zentalis Pharmaceuticals, Inc.
ZNTL
(1.5)3,47 USD
-39.89% ROA
-44.23% ROE
-1.11x PER
216.168.320,00 USD
11.51% DER
0% Yield
-456.25% NPM
Zentalis Pharmaceuticals, Inc. Stock Analysis
Zentalis Pharmaceuticals, Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
DER
The stock has a low debt to equity ratio (9%), which means it has a small amount of debt compared to the ownership it holds |
|
| 2 |
Assets Growth
With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity. |
|
| 3 |
PBV
The stock's PBV ratio (1.32x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns. |
|
| 4 |
Graham Number
The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity. |
|
| 5 |
ROE
Negative ROE (-61.84%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity. |
|
| 6 |
ROA
The stock's ROA (-44.32%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment. |
|
| 7 |
Revenue Growth
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice. |
|
| 8 |
Net Profit Growth
Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option. |
|
| 9 |
Dividend Growth
Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns. |
|
| 10 |
Dividend
Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges. |
|
| 11 |
Buffet Intrinsic Value
Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value. |
Zentalis Pharmaceuticals, Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Buy |
| 2 | MACD | Buy |
| 3 | RSI | Sell |
| 4 | Stoch RSI | Sell |
Zentalis Pharmaceuticals, Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2018 | 14.000 | |
| 2019 | 0 | 0% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
| 2023 | 0 | 0% |
| 2024 | 0 | 0% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2018 | 18.921.000 | |
| 2019 | 38.386.000 | 50.71% |
| 2020 | 84.901.000 | 54.79% |
| 2021 | 175.601.000 | 51.65% |
| 2022 | 172.734.000 | -1.66% |
| 2023 | 187.060.000 | 7.66% |
| 2023 | 235.158.000 | 20.45% |
| 2024 | 193.544.000 | -21.5% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2018 | 4.876.000 | |
| 2019 | 8.459.000 | 42.36% |
| 2020 | 33.886.000 | 75.04% |
| 2021 | 40.941.000 | 17.23% |
| 2022 | 54.553.000 | 24.95% |
| 2023 | 63.812.000 | 14.51% |
| 2023 | 59.398.000 | -7.43% |
| 2024 | 67.048.000 | 11.41% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2018 | -23.732.000 | |
| 2019 | -46.734.000 | 49.22% |
| 2020 | -119.470.000 | 60.88% |
| 2021 | -268.525.000 | 55.51% |
| 2022 | -233.274.000 | -15.11% |
| 2023 | -278.316.000 | 16.18% |
| 2023 | -247.599.000 | -12.41% |
| 2024 | -259.284.000 | 4.51% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2018 | 14.000 | |
| 2019 | -111.000 | 112.61% |
| 2020 | -160.000 | 30.63% |
| 2021 | -544.000 | 70.59% |
| 2022 | -1.426.000 | 61.85% |
| 2023 | 0 | 0% |
| 2023 | -1.389.000 | 100% |
| 2024 | -1.308.000 | -6.19% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2018 | -21.067.000 | |
| 2019 | -46.378.000 | 54.58% |
| 2020 | -118.548.000 | 60.88% |
| 2021 | -164.262.000 | 27.83% |
| 2022 | -220.831.000 | 25.62% |
| 2023 | -222.112.000 | 0.58% |
| 2023 | -292.191.000 | 23.98% |
| 2024 | -353.108.000 | 17.25% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2018 | -1 | |
| 2019 | -1 | 0% |
| 2020 | -3 | 50% |
| 2021 | -4 | 33.33% |
| 2022 | -4 | 25% |
| 2023 | -3 | -33.33% |
| 2023 | -4 | 25% |
| 2024 | -5 | 0% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2018 | -24.478.000 | |
| 2019 | -39.495.000 | 38.02% |
| 2020 | -87.583.000 | 54.91% |
| 2021 | -160.200.000 | 45.33% |
| 2022 | -166.299.000 | 3.67% |
| 2023 | -208.405.000 | 20.2% |
| 2023 | -38.756.000 | -437.74% |
| 2024 | -35.320.000 | -9.73% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2018 | -24.251.000 | |
| 2019 | -39.143.000 | 38.05% |
| 2020 | -86.825.000 | 54.92% |
| 2021 | -154.093.000 | 43.65% |
| 2022 | -163.751.000 | 5.9% |
| 2023 | -207.822.000 | 21.21% |
| 2023 | -38.665.000 | -437.49% |
| 2024 | -35.139.000 | -10.03% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2018 | 227.000 | |
| 2019 | 352.000 | 35.51% |
| 2020 | 758.000 | 53.56% |
| 2021 | 6.107.000 | 87.59% |
| 2022 | 2.548.000 | -139.68% |
| 2023 | 583.000 | -337.05% |
| 2023 | 91.000 | -540.66% |
| 2024 | 181.000 | 49.72% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2018 | 32.306.000 | |
| 2019 | 83.597.000 | 61.36% |
| 2020 | 358.172.000 | 76.66% |
| 2021 | 365.010.000 | 1.87% |
| 2022 | 434.245.000 | 15.94% |
| 2023 | 437.391.000 | 0.72% |
| 2023 | 481.897.000 | 9.24% |
| 2024 | 382.581.000 | -25.96% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2018 | 40.998.000 | |
| 2019 | 102.657.000 | 60.06% |
| 2020 | 365.555.000 | 71.92% |
| 2021 | 454.507.000 | 19.57% |
| 2022 | 539.310.000 | 15.72% |
| 2023 | 562.027.000 | 4.04% |
| 2023 | 585.715.000 | 4.04% |
| 2024 | 491.680.000 | -19.13% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2018 | 8.692.000 | |
| 2019 | 19.060.000 | 54.4% |
| 2020 | 32.178.000 | 40.77% |
| 2021 | 90.025.000 | 64.26% |
| 2022 | 105.286.000 | 14.49% |
| 2023 | 124.636.000 | 15.53% |
| 2023 | 103.818.000 | -20.05% |
| 2024 | 109.099.000 | 4.84% |
Zentalis Pharmaceuticals, Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 0.6
- Net Income per Share
- -2.74
- Price to Earning Ratio
- -1.11x
- Price To Sales Ratio
- 5.07x
- POCF Ratio
- -1.3
- PFCF Ratio
- -1.3
- Price to Book Ratio
- 0.56
- EV to Sales
- 5.23
- EV Over EBITDA
- -0.99
- EV to Operating CashFlow
- -1.34
- EV to FreeCashFlow
- -1.34
- Earnings Yield
- -0.9
- FreeCashFlow Yield
- -0.77
- Market Cap
- 0,22 Bil.
- Enterprise Value
- 0,22 Bil.
- Graham Number
- 18.22
- Graham NetNet
- 4.47
Income Statement Metrics
- Net Income per Share
- -2.74
- Income Quality
- 0.85
- ROE
- -0.44
- Return On Assets
- -0.4
- Return On Capital Employed
- -0.52
- Net Income per EBT
- 1
- EBT Per Ebit
- 0.88
- Ebit per Revenue
- -5.17
- Effective Tax Rate
- -0
Margins
- Sales, General, & Administrative to Revenue
- 1.52
- Research & Developement to Revenue
- 4.6
- Stock Based Compensation to Revenue
- 1.25
- Gross Profit Margin
- 0.97
- Operating Profit Margin
- -5.17
- Pretax Profit Margin
- -4.56
- Net Profit Margin
- -4.56
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -2.34
- Free CashFlow per Share
- -2.35
- Capex to Operating CashFlow
- -0
- Capex to Revenue
- 0.01
- Capex to Depreciation
- 0.36
- Return on Invested Capital
- -0.52
- Return on Tangible Assets
- -0.4
- Days Sales Outstanding
- 0
- Days Payables Outstanding
- 5584.28
- Days of Inventory on Hand
- 0
- Receivables Turnover
- 0
- Payables Turnover
- 0.07
- Inventory Turnover
- 0
- Capex per Share
- 0.01
Balance Sheet
- Cash per Share
- 6,00
- Book Value per Share
- 5,39
- Tangible Book Value per Share
- 5.33
- Shareholders Equity per Share
- 5.39
- Interest Debt per Share
- 0.7
- Debt to Equity
- 0.12
- Debt to Assets
- 0.09
- Net Debt to EBITDA
- -0.03
- Current Ratio
- 6.59
- Tangible Asset Value
- 0,38 Bil.
- Net Current Asset Value
- 0,33 Bil.
- Invested Capital
- 415471001
- Working Capital
- 0,37 Bil.
- Intangibles to Total Assets
- 0.01
- Average Receivables
- 0,00 Bil.
- Average Payables
- 0,02 Bil.
- Average Inventory
- 0
- Debt to Market Cap
- 0.2
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
Zentalis Pharmaceuticals, Inc. Profile
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
- CEO
- Dr. Kimberly Lynn Blackwell M.
- Employee
- 124
- Address
-
1359 Broadway
New York, 10018
Zentalis Pharmaceuticals, Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Dr. Mark Lackner Ph.D. Chief Scientific Officer |
70 |
| 2 |
Dr. Kyle Rasbach Ph.D., Pharm.D. Chief Business Officer |
70 |
| 3 |
Ms. Andrea Paul J.D. Chief Legal Officer & Corporate Secretary |
70 |
| 4 |
Mr. Cameron S. Gallagher M.B.A. Co-Founder, President, Interim Chief Financial Officer, Interim Treasurer & Director |
70 |
| 5 |
Mr. Vincent Vultaggio Vice President of Finance & Interim Principal Accounting Officer |
70 |
| 6 |
Dr. Kimberly Lynn Blackwell M.D. Chief Executive Officer & Director |
70 |
| 7 |
Ms. Kimberly Freeman Chief Strategy Officer |
70 |
Zentalis Pharmaceuticals, Inc. Competitors
